Clinical Report: Disparities in US Federal Cancer Research Funding Relative to Disease Burden
Overview
This study reveals that US federal research funding is disproportionately allocated, favoring cancers with lower lethality such as breast and prostate cancer, while highly lethal cancers like small cell lung and pancreatic cancer receive substantially less funding per estimated death. Mortality-to-incidence ratios (MIRs) highlight the clinical urgency of these lethal cancers, underscoring a misalignment between funding and disease burden.
Background
Cancer incidence alone inadequately reflects public health impact because it does not account for disease lethality. Mortality, survival, and MIRs provide complementary measures that better capture clinical urgency and unmet needs. Federal research funding decisions are influenced by scientific opportunity, historical investment, and congressional appropriations, but may not fully align with current disease burden. Evaluating funding relative to outcome-based metrics can identify gaps and guide resource allocation.
Data Highlights
Cancer Type
Estimated Deaths
MIR
NIH Funding (FY 2025)
Funding per Estimated Death
Small Cell Lung Cancer (SCLC)
Not specified separately; part of 151,401 lung cancer deaths
>0.85
$62 million
$2,818
Non–Small Cell Lung Cancer (NSCLC)
Not specified separately; part of 151,401 lung cancer deaths
Not specified
$227 million
Not specified
Pancreatic Cancer
49,211
>0.85
$440 million
$8,945
Breast Cancer
22,606
<0.10
$1.58 billion
$69,800
Prostate Cancer
5,219
<0.10
Not specified
$126,992
Key Findings
Cancers with the highest lethality, such as small cell lung and pancreatic cancers (MIR > 0.85), receive disproportionately lower federal research funding per estimated death.
Breast and prostate cancers, with low MIRs (<0.10), receive substantially higher funding per estimated death despite lower mortality rates.
NIH research funding totals $1.58 billion for breast cancer compared to $62 million for small cell lung cancer and $440 million for pancreatic cancer.
Funding patterns reflect historical investments, advocacy, and prior therapeutic breakthroughs rather than current clinical urgency.
Industry investment tends to track incidence rather than lethality, potentially reinforcing funding imbalances.
Despite recognition of these disparities for over a decade, federal funding allocation remains largely unchanged.
Clinical Implications
Clinicians and policymakers should advocate for research funding that better aligns with cancer lethality and unmet clinical needs, prioritizing highly lethal cancers to reduce mortality and suffering. A composite funding framework incorporating incidence, mortality, survival, and social impact factors could optimize resource allocation and improve outcomes for underserved cancer types.
Conclusion
Federal cancer research funding in the US remains misaligned with disease burden, favoring less lethal cancers. Integrating outcome-based measures into funding decisions could enhance the impact of research investments on clinical outcomes.
References
NIH Portfolio Reports 2025 -- Federal Cancer Research Funding Data
Surveillance, Epidemiology, and End Results Program 2015-2021 -- Cancer Incidence and Survival Data
North American Association of Central Cancer Registries 2022 -- Cancer in North America Explorer
